Other studies have been carried out to investigate mechanisms of resistance to selective Braf inhibitors in CRC and suggested that resistance to Braf inhibition is also mediated by EGFR-reactivation of the Raf/MEK/ERK signaling pathway [23]. Here, EGFR is linked to colorectal carcinoma.